Therapeutic use of Tadekinig alfa in NLRC4 mutation and XIAP deficiency

Therapeutic use of Tadekinig alfa in NLRC4 mutation and XIAP deficiency

Contact

 If you are interested in participating in the study or want to learn more, please get in touch. Contact us
This study is no longer recruiting.

Description
This is a clinical trial to study the use of Tadekinig alfa or placebo (medication) in the treatment of NLRC4 MAS mutation or XIAP deficiency. This study involves taking the medication every 48 hours for up to 26 weeks. Participants will also be required to attend up to 14 in-person study visits to review their disease state while they are taking the medication. Compensation for time and travel related to study visits may be provided to qualified participants.

Eligibility and criteria
IRB Number:
17-013986
Eligible age range:
1 months - 17 years
Clinical trial phase:
Phase III
Official title:
Multicenter Double-Blind, Placebo-Controlled, Randomized Withdrawal Trial With Tadekinig alfa (r-hIL-18BP) in Patients with IL-18 Driven Monogenic Auto-Inflammatory Conditions: NLRC4 Mutation and XIAP Deficiency

What to expect

Related specialties
Smiling CHOP patient holding shopping bag

We need families like you

Your time and participation make a difference in supporting the work of the Research Institute and children in our community. Learn more about opportunities to participate in our research.